The effects of [Arg14, Lys15] nociceptin/orphanin FQ, a highly potent agonist of the NOP receptor, on in vitro and in vivo gastrointestinal functions

Peptides. 2005 Sep;26(9):1590-7. doi: 10.1016/j.peptides.2005.02.018. Epub 2005 Mar 19.

Abstract

Nociceptin/orphanin FQ (N/OFQ) administered into the lateral left cerebral ventricle of rats has been reported to inhibit in vivo gut motor and secretory functions. Recently, a novel N/OFQ analog, [Arg14, Lys15] N/OFQ, was synthesized and demonstrated to behave as a highly potent agonist at the human recombinant N/OFQ peptide (NOP) receptors and to produce long-lasting effects in vivo in mice compared with the natural ligand N/OFQ. In the present study, the pharmacological profile of [Arg14, Lys15] N/OFQ was further evaluated and compared with that of N/OFQ in vitro on guinea pig exocrine pancreas and in vivo on gastric emptying, colonic propulsion and gastric acid secretion in rats. [Arg14, Lys15] N/OFQ and N/OFQ significantly decreased the KCl-evoked amylase secretion from isolated pancreatic lobules of the guinea pig. In in vivo experiments, [Arg14, Lys15] N/OFQ mimicked the effects of N/OFQ, inducing, after intracerebroventricular injection, a delay (up to 70%) in the gastric emptying of a phenol red meal, an increase (about 40 times) of the mean bead colonic expulsion time and a decrease (up to 90%) of gastric acid secretion in water loaded rats after 90 min pylorus ligature. In all these assays, [Arg14, Lys15] N/OFQ was more effective than N/OFQ, and its effective doses were at least 10-fold lower than N/OFQ effective doses. The highly selective NOP receptor antagonist, UFP-101, decreased the efficacy of [Arg14, Lys15] N/OFQ in in vitro and in vivo assays above reported. These findings: (a) show that pancreatic NOP receptors mediate an in vitro inhibitory effect on stimulated guinea pig amylase secretion; (b) confirm that the stimulation of central NOP receptors exerts an inhibitory control on gastric emptying, colonic motility and gastric secretion in rats and (c) put in evidence that [Arg14, Lys15] N/OFQ, being more potent and effective than the natural ligand N/OFQ, represents a new pharmacological tool for the study of the physiological and pharmacological roles mediated by the N/OFQ-NOP receptor system.

MeSH terms

  • Amylases / metabolism
  • Animals
  • Digestive System / drug effects*
  • Dose-Response Relationship, Drug
  • Gastric Acid / metabolism
  • Gastric Emptying / drug effects
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism
  • Gastrointestinal Transit / drug effects
  • Guinea Pigs
  • In Vitro Techniques
  • Ligation
  • Male
  • Naloxone / pharmacology
  • Narcotic Antagonists
  • Nociceptin
  • Nociceptin Receptor
  • Opioid Peptides / pharmacology*
  • Pancreas, Exocrine / drug effects
  • Pancreas, Exocrine / metabolism
  • Potassium Chloride / pharmacology
  • Pylorus / surgery
  • Rats
  • Rats, Wistar
  • Receptors, Opioid / agonists*
  • Vasodilator Agents / pharmacology

Substances

  • (Nphe(1),Arg(14),Lys(15))N-OFQ NH(2)
  • Narcotic Antagonists
  • Opioid Peptides
  • Receptors, Opioid
  • Vasodilator Agents
  • nociceptin, Arg(14)-Lys(15)-
  • Naloxone
  • Potassium Chloride
  • Amylases
  • Nociceptin Receptor